GleamWall
中文EN

ATOS ATOSSA THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1488039 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-14.8%
TTM EPS YoY31.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-96.9%
ROA-82.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets17.8%
Debt / equity0.00x
Current ratio5.35x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio1.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$21.18M$14.12M$17.33M$15.08M$9.21M
SG&A expense$15.96M$13.50M$14.04M$12.61M$11.31M
Operating income-$37.14M-$27.62M-$31.38M-$27.69M-$20.52M
Pretax income-$34.77M-$25.50M-$30.09M-$26.96M-$20.61M
Income tax$0$0$0$0$0
Net income-$34.77M-$25.50M-$30.09M-$26.96M-$20.61M
EBITDA-$37.12M-$27.60M-$31.35M-$27.68M-$20.50M
EPS (basic)-4.04-3.04-0.24-0.21-0.18
EPS (diluted)-4.04-3.04-0.24-0.21-0.18
Weighted avg. shares (diluted)8.61M8.39M126.08M126.62M116,950
Balance sheet
Cash & equivalents$41.30M$71.08M$88.46M$110.89M$136.38M
Current assets$45.62M$74.46M$92.22M$118.20M$141.24M
PP&E, net————$20,000
Intangibles————$54,000
Total assets$47.61M$76.44M$96.25M$123.53M$141.26M
Current liabilities$8.26M$4.97M$5.24M$5.57M$3.13M
Total liabilities$8.26M$4.97M$5.24M$5.57M$3.13M
Shareholders' equity$39.35M$71.48M$91.02M$117.96M$138.14M
Shares outstanding8.61M8.61M125.30M126.62M126.62M
Cash flow statement
Operating cash flow-$29.76M-$21.03M-$20.94M-$20.76M-$16.47M
Capital expenditure$23,000$19,000$14,000$27,000$9,000
Free cash flow-$29.79M-$21.05M-$20.95M-$20.79M-$16.48M
Investing cash flow-$23,000-$19,000-$14,000-$4.73M-$9,000
Financing cash flow$0$3.67M-$1.48M$0$113.30M
Depreciation & amortization$16,000$17,000$23,000$8,000$23,000
Stock-based compensation$2.65M$2.29M$4.62M$6.79M$5.27M
Share buybacks—$0$1.48M$0—

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.